Researchers writing in JAMA Network Open report that for patients with metastatic clear cell renal cell carcinoma, removing the kidney and its primary tumor is not associated with improved overall ...

Cytoreductive nephrectomy, a standard approach for de novo metastatic renal cell carcinoma in the era of cytokine therapy, has been upheld during the age of targeted therapy on the basis of ...

Please provide your email address to receive an email when new articles are posted on . Pretreatment with sunitinib followed by deferred cytoreductive nephrectomy did not improve 28-week ...

The presentation of renal cancer in patients with flank pain, an abdominal or flank mass, and hematuria is now uncommon (<5% of cases). About 70% of patients are diagnosed following incidental ...

A Canadian study recently assessed 709 patients with intermediate- and high-risk synchronous mRCC with or without sarcomatoid features. Most patients had clear cell histology and were treated with ...

Source: Getty Images In a study, the Selection for Cytoreductive Nephrectomy (SCREEN) score demonstrated superiority in predicting first-year mortality among patients with metastatic kidney cancer ...

Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy. If you have the appropriate software installed, you can download article citation data to the ...

Cytoreductive nephrectomy (CN) is increasingly less likely to be used for mRCC, according to an analysis presented at ASCO's Genitourinary Cancers Symposium. "The evolving treatment landscape in mRCC ...

Please provide your email address to receive an email when new articles are posted on . Thirty-five percent of patients who received targeted therapy for renal cell carcinoma underwent cytoreductive ...

Renal cell carcinoma presents with metastatic disease in approximately 30% of patients at the time of diagnosis. Cytoreductive nephrectomy (CN) of the primary tumor in the face of metastatic disease ...

Upfront cytoreductive nephrectomy for mRCC patients with certain clinical characteristics may enable them to defer systemic therapy for a prolonged interval. Investigators identified a subgroup of ...

Although retrospective data supported a similar survival benefit for cytoreductive nephrectomy in the targeted therapy era as it did for the initial immunotherapy era (1992 to 2006), level 1 evidence ...